CCR5阻滞剂马拉韦罗的药理与临床评价

Pharmacology and clinical evaluation of maraviroc,a CCR5 antagonist

马拉韦罗是一种选择性、可逆的小分子抑制剂,能与细胞膜表面人化学趋化因子受体-5(CCR5)和HIV-1gp120相互作用,抑制CCR5-tropic HIV-1病毒进入细胞,是一种很有前途的新型抗病毒药。现对其药理作用、药动学、药物相互作用及对仅感染CCR5-tropic HIV-1的成年患者的疗效和安全性进行了综述。

Maraviroe is a selective, slowly reversible, small molecule antagonist that interacts with human CCR5 and HIV-1 gp120, and prevents CCR5-tropic HIV-1 entry into cells. In this paper, we reviewed the pharmaeology, pharmacokinetics and drug interactions, the efficacy and safety in the treatment for adult patients infected only with detectable CCR5-tropie HIV-1.